Omnicare, Inc. (OCR) shares are up approximately 8.5% today on volume of almost 3.7 million, which is much higher than the average of about 1.4 million. As a result, this provider of pharmaceutical care for the elderly will end the week as a top-performing Zacks #1 Rank company.

< ?DART(15);?> Over the past 2 months, earnings estimates for this year and next have advanced 6.7% and 4.9%, respectively. Furthermore, current data suggests that 2010 profit could improve as much as 10% from 2009, which is an encouraging trend.

With no revisions in the past month, analysts have been sitting on their hands in regard to OCR for a while; perhaps waiting for its first-quarter report on Apr 30. Expectations for the quarter are at 61 cents, almost 9% better than 2 months ago.

OCR reported fourth-quarter adjusted earnings per share of 66 cents

...

Omnicare (OCR) is staging a nice rebound after seeing to recent lows. Analysts are upbeat on the company, boosting full-year forecasts from $2.41 per share to $2.56 over the past 3 months. < ?DART(15);?>

Company Description

Omnicare, Inc. provides pharmaceutical care for the elderly. Omnicare serves residents in long-term care facilities and other chronic care settings comprising beds in fourteen states, the District of Columbia and Canada.

Omnicare is the largest U.S. provider of professional pharmacy, related consulting and data management services for skilled nursing, assisted living and other institutional healthcare providers as well as for hospice patients in homecare and other settings.

Omnicare's pharmacy services also include distribution and patient assistance services for specialty pharmaceuticals. Omnicare offers clinical research services for the pharmaceutical and biotechnology industries in thirty countries worldwide

Robust Results

The company recently announced fourth-quarter adjusted earnings of 66 cents per share, exceeding the consensus estimate by 5%

...

Omnicare, Inc. (...

The five best performing stocks on the Zacks #1 Rank List last week were: Cadence Pharmaceuticals, Inc. (...